Inhibitors of retroviral DNA polymerase: their implication in the treatment of AIDS.
Compared to other T-lymphotropic human retroviruses, human T-cell leukemia (lymphotropic) virus I (HTLV-I) and HTLV-II, the acquired immunodeficiency syndrome (AIDS)-associated virus, HTLV-III, is a nontransforming cytopathic virus without immortalizing activity. Thus the virus replication is an important event in the manifestation of this disease, and the interruption of viral replication offers an important strategy for the control of AIDS. For this reason we have purified the reverse transcriptase (RT) from HTLV-III and from HTLV-III infected cells to study the structure-activity relationship of RT inhibitors developed in our laboratory. The cellular DNA polymerases from H9 cells were also purified to study the selectivity of RT inhibitors. Purified HTLV-III RT has several distinguishing features: (a) unlike the HTLV-I enzyme it is highly stable and can be kept for several weeks without any loss of activity; (b) using identical procedures of isolation the HTLV-III enzyme shows a much higher activity than does the enzyme from HTLV-I; (c) the Vmax for HTLV-III RT is by severalfold higher than that for the HTLV-I enzyme in the presence of (rC)n X (dG)12 and (rCm)n X (dG)12, and besides the usual template-primers used for RT assay this enzyme has a relatively high affinity for (rAm)n X (dT)12; and (d) the cationic requirements for the transcription of various template-primers are unusual. The purified enzyme has a molecular weight of 95,000-98,000, as judged by the gel filtration method. The purified HTLV-III RT was inhibited by a partially thiolated polycytidylic acid (5-mercaptopolycytidylic acid); the cellular DNA polymerase beta from H9 cells was not sensitive to 5-mercaptopolycytidylic acid. Germanin (synonym, suramin), an antiprotozoan drug, also inhibits HTLV-III RT activity, but the DNA polymerase alpha activity was also sensitive to Germanin. The nonspecific effect of Germanin is probably due to the high content of sulfonic acid residues. This paper describes new approaches for designing specific inhibitors of retroviral reverse transcriptases which may be useful in developing a potential drug against AIDS.
P
P
Chandra
A
A
Vogel
T
T
Gerber
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D002460:Cell Line; D004253:DNA Nucleotidylexotransferase / Q000037:antagonists & inhibitors; D017977:Deltaretrovirus / Q000201:enzymology* / Q000502:physiology; D006801:Humans; D007700:Kinetics; D008970:Molecular Weight; D019384:Nucleic Acid Synthesis Inhibitors; D011061:Poly A / Q000494:pharmacology; D011066:Poly C / Q000494:pharmacology*; D011131:Polyribonucleotides / Q000494:pharmacology*; D012194:RNA-Directed DNA Polymerase / Q000302:isolation & purification / Q000378:metabolism; D012190:Retroviridae / Q000201:enzymology; D018894:Reverse Transcriptase Inhibitors; D013329:Structure-Activity Relationship; D013498:Suramin / Q000494:pharmacology*; D013873:Thionucleotides / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects
C010218:5-mercaptopolycytidylic acid; D019384:Nucleic Acid Synthesis Inhibitors; D011131:Polyribonucleotides; D018894:Reverse Transcriptase Inhibitors; D013873:Thionucleotides; D011061:Poly A; D011066:Poly C; D013498:Suramin; D004253:DNA Nucleotidylexotransferase; D012194:RNA-Directed DNA Polymerase